Christenson Johan 4
4 · Aprea Therapeutics, Inc. · Filed Oct 7, 2019
Insider Transaction Report
Form 4
Christenson Johan
Director
Transactions
- Conversion
Common Stock
2019-10-07+1,661,382→ 1,671,941 total(indirect: See footnote) - Conversion
Common Stock
2019-10-07+427,496→ 2,099,437 total(indirect: See footnote) - Purchase
Common Stock
2019-10-07$15.00/sh+266,667$4,000,005→ 2,366,104 total(indirect: See footnote) - Conversion
Series C Convertible Preferred Stock
2019-10-07−427,496→ 0 total(indirect: See footnote)→ Common Stock (427,496 underlying) - Conversion
Series B Convertible Preferred Stock
2019-10-07−1,661,382→ 0 total(indirect: See footnote)→ Common Stock (1,661,382 underlying)
Footnotes (2)
- [F1]These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]These Shares and Preferred Stock are held directly by HealthCap VII, L.P. ("HCLP"). HealthCap VII GP SA ("HCSA") is the sole general partner of HCLP and has voting and investment control over the Shares and Preferred Stock held by HCLP. The reporting person has an indirect interest in HCSA and is an employee of HealthCap VII Advisor AB. The reporting person disclaims beneficial ownership of Shares and Preferred Stock held by HCLP except to the extent of any pecuniary interest therein.